515 related articles for article (PubMed ID: 29788127)
41. Safety of Tofacitinib in a Real-World Cohort of Patients With Ulcerative Colitis.
Deepak P; Alayo QA; Khatiwada A; Lin B; Fenster M; Dimopoulos C; Bader G; Weisshof R; Jacobs M; Gutierrez A; Ciorba MA; Christophi GP; Patel A; Hirten RP; Colombel JF; Rubin DT; Ha C; Beniwal-Patel P; Ungaro RC; Syal G; Pekow J; Cohen BL; Yarur A
Clin Gastroenterol Hepatol; 2021 Aug; 19(8):1592-1601.e3. PubMed ID: 32629130
[TBL] [Abstract][Full Text] [Related]
42. Tofacitinib for the Treatment of Ulcerative Colitis: An Integrated Summary of up to 7.8 Years of Safety Data from the Global Clinical Programme.
Sandborn WJ; D'Haens GR; Sands BE; Panaccione R; Ng SC; Lawendy N; Kulisek N; Modesto I; Guo X; Mundayat R; Su C; Vranic I; Panés J
J Crohns Colitis; 2023 Apr; 17(3):338-351. PubMed ID: 36124702
[TBL] [Abstract][Full Text] [Related]
43. JAK Inhibitors Safety in Ulcerative Colitis: Practical Implications.
Agrawal M; Kim ES; Colombel JF
J Crohns Colitis; 2020 Aug; 14(Supplement_2):S755-S760. PubMed ID: 32006031
[TBL] [Abstract][Full Text] [Related]
44. Janus kinase inhibition with tofacitinib: changing the face of inflammatory bowel disease treatment.
Vuitton L; Koch S; Peyrin-Biroulet L
Curr Drug Targets; 2013 Nov; 14(12):1385-91. PubMed ID: 23627915
[TBL] [Abstract][Full Text] [Related]
45. Tofacitinib for the treatment of ulcerative colitis.
Fernández-Clotet A; Castro-Poceiro J; Panés J
Expert Rev Clin Immunol; 2018 Nov; 14(11):881-892. PubMed ID: 30285500
[TBL] [Abstract][Full Text] [Related]
46. Positioning of tofacitinib in treatment of ulcerative colitis: a global perspective.
Mishra S; Jena A; Kakadiya R; Sharma V; Ahuja V
Expert Rev Gastroenterol Hepatol; 2022 Aug; 16(8):737-752. PubMed ID: 35875997
[TBL] [Abstract][Full Text] [Related]
47. A case of new-onset vitiligo in a patient on tofacitinib and brief review of paradoxical presentations with other novel targeted therapies.
Nguyen JK; Schlichte MJ; Jogi R; Alikhan M; Patel AB
Dermatol Online J; 2020 Mar; 26(3):. PubMed ID: 32609446
[TBL] [Abstract][Full Text] [Related]
48. Safety of Tofacitinib in the Treatment of Rheumatoid Arthritis in Latin America Compared With the Rest of the World Population.
Castañeda OM; Romero FJ; Salinas A; Citera G; Mysler E; Rillo O; Radominski SC; Cardiel MH; Jaller JJ; Alvarez-Moreno C; Ponce de Leon D; Castelli G; García EG; Kwok K; Rojo R
J Clin Rheumatol; 2017 Jun; 23(4):193-199. PubMed ID: 28145906
[TBL] [Abstract][Full Text] [Related]
49. Efficacy of tofacitinib treatment in ulcerative colitis.
Panés J; Gisbert JP
Gastroenterol Hepatol; 2019; 42(6):403-412. PubMed ID: 31101342
[TBL] [Abstract][Full Text] [Related]
50. The emerging safety profile of JAK inhibitors in rheumatic disease.
Winthrop KL
Nat Rev Rheumatol; 2017 Apr; 13(4):234-243. PubMed ID: 28250461
[TBL] [Abstract][Full Text] [Related]
51. Safety of JAK inhibitor use in patients with rheumatoid arthritis who developed herpes zoster after receiving JAK inhibitors.
Choi W; Ahn SM; Kim YG; Lee CK; Yoo B; Hong S
Clin Rheumatol; 2022 Jun; 41(6):1659-1663. PubMed ID: 35157164
[TBL] [Abstract][Full Text] [Related]
52. Impact of Concomitant Corticosteroids on Tofacitinib Induction Efficacy and Infection Rates in Ulcerative Colitis.
Lichtenstein GR; Cohen BL; Salese L; Modesto I; Wang W; Chan G; Ahmed HM; Su C; Peyrin-Biroulet L
Dig Dis Sci; 2023 Jun; 68(6):2624-2634. PubMed ID: 36739367
[TBL] [Abstract][Full Text] [Related]
53. Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors.
Gladman D; Rigby W; Azevedo VF; Behrens F; Blanco R; Kaszuba A; Kudlacz E; Wang C; Menon S; Hendrikx T; Kanik KS
N Engl J Med; 2017 Oct; 377(16):1525-1536. PubMed ID: 29045207
[TBL] [Abstract][Full Text] [Related]
54. Outcomes of Pregnancies With Maternal/Paternal Exposure in the Tofacitinib Safety Databases for Ulcerative Colitis.
Mahadevan U; Dubinsky MC; Su C; Lawendy N; Jones TV; Marren A; Zhang H; Graham D; Clowse MEB; Feldman SR; Baumgart DC
Inflamm Bowel Dis; 2018 Nov; 24(12):2494-2500. PubMed ID: 29982686
[TBL] [Abstract][Full Text] [Related]
55. Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis.
Mease P; Hall S; FitzGerald O; van der Heijde D; Merola JF; Avila-Zapata F; Cieślak D; Graham D; Wang C; Menon S; Hendrikx T; Kanik KS
N Engl J Med; 2017 Oct; 377(16):1537-1550. PubMed ID: 29045212
[TBL] [Abstract][Full Text] [Related]
56. Safety signal detection and evaluation in clinical development programs: A case study of tofacitinib.
Dasic G; Jones T; Frajzyngier V; Rojo R; Madsen A; Valdez H
Pharmacol Res Perspect; 2018 Feb; 6(1):. PubMed ID: 29417755
[TBL] [Abstract][Full Text] [Related]
57. Comparison of risks of cancer, infection, and MACEs associated with JAK inhibitor and TNF inhibitor treatment: a multicentre cohort study.
Uchida T; Iwamoto N; Fukui S; Morimoto S; Aramaki T; Shomura F; Aratake K; Eguchi K; Ueki Y; Kawakami A
Rheumatology (Oxford); 2023 Oct; 62(10):3358-3365. PubMed ID: 36794922
[TBL] [Abstract][Full Text] [Related]
58. Tofacitinib for the treatment of psoriasis and psoriatic arthritis.
Ighani A; Georgakopoulos JR; Yeung J
G Ital Dermatol Venereol; 2020 Aug; 155(4):400-410. PubMed ID: 32348084
[TBL] [Abstract][Full Text] [Related]
59. Tofacitinib use in ulcerative colitis: An expert consensus for day-to-day clinical practice.
Banerjee R; Sharma V; Patel R; Jena A; Pal P; Raghunathan N; Kumar A; Sood A; Puri AS; Goswami B; Desai D; Mekala D; Ramesh GN; Rao GV; Peddi K; Philip M; Tandon M; Bhatia S; Godbole S; Bhatia S; Ghoshal UC; Dutta U; Midha V; Prasad VGM; Reddy DN
Indian J Gastroenterol; 2024 Feb; 43(1):22-35. PubMed ID: 38347433
[TBL] [Abstract][Full Text] [Related]
60. Efficacy and safety of tofacitinib dose de-escalation and dose escalation for patients with ulcerative colitis: results from OCTAVE Open.
Sands BE; Armuzzi A; Marshall JK; Lindsay JO; Sandborn WJ; Danese S; Panés J; Bressler B; Colombel JF; Lawendy N; Maller E; Zhang H; Chan G; Salese L; Tsilkos K; Marren A; Su C
Aliment Pharmacol Ther; 2020 Jan; 51(2):271-280. PubMed ID: 31660640
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
